rejuvant life tabs

Ziegler plans additional $50 million AgeTech fund

Latest articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...
Rejuvant

Ziegler Link-Age Fund targets start-ups with a focus on independent living, fall-risk and senior living environments.

Founded in 1902, specialty investment firm Ziegler is one of the oldest independent investment banks in the United States, outside of Wall Street. The firm specialises in the healthcare, senior living and education sectors, and in 2014 launched its first fund focused specifically on companies targeting aging – the Ziegler Link-Age Fund. The first fund raised in 2014 was for $26 million, the second in 2017 was $37 million and the next fund, planned for later this year, is expected to be $50 million.

Longevity Technology Zeigler VC

The fund is one of the first to focus on the aging market and companies that provide innovative products, services and technologies to meet the growing needs of seniors and senior living providers in this changing era of healthcare reform.

Dan Hermann is President and CEO of Ziegler and was instrumental in the creation of the Ziegler Link-Age Fund.

“We’re the leading investment bank for the not-for-profit senior living marketplace, for purposes of capital raising,” says Hermann. A fact that put Ziegler in the ideal position to become an investor in products and services that benefit the senior living sector.

“As a result of our very large senior living client base we wanted to pursue the idea of a venture fund for tech-enabled and tech-driven services selling into the aging services marketplace,” adds Hermann. “And not just companies selling into the senior living providers themselves, but also those targeting the home care, health system and payer markets.”


Unlike traditional funds which raise capital from institutional investors, Ziegler’s Longevity fund capital is predominantly raised from senior living providers and industry professionals.


 

“We made it very accessible, with a minimum investment of $250,000 to make it easier for people in the sector to get involved with looking at all these great ideas,” says Hermann. “One of the greatest attributes we bring to our portfolio companies is access to our network of senior living providers.”

Once Ziegler has vetted a company and decided that it has potential, then the next phase is to present the investment prospect to the company’s limited partners – senior living operators across the United States. This is done via webinars or at events like the firm’s annual symposium.

The Ziegler Link-Age fund is focused on companies that are already up and running and in their market with a valid product, and looking to scale-up.

“There are hundreds of good ideas out there and everyone is looking for a portfolio manager, but we’re looking at late Seed and early Series A level investments,” explains Hermann. “We’re typically talking $5 million to $15 million funding rounds, and our average investment in these rounds is $2 million to $3 million.”


Ziegler has seen over 1,700 companies, vetted over 600, conducted 99 webinars and invested in 25 …


 

Since starting the first fund in 2014, Ziegler has seen over 1,700 companies, vetted over 600, conducted 99 webinars and invested in 25 – an interesting indication of their pipeline and how selective the company has been.

The characteristics of the companies Ziegler invests in tend to follow fairly typical patterns – strong leadership, a differentiated offering, demonstrated knowledge of the sector and so on. But Hermann also likes companies with a clear and realistic vision of where they want to get to.

Elevant

“You don’t need to become national to be successful,” says Hermann. “We like companies that have a good understanding of the capital they need to become a success – whether that’s nationally or at a state or regional level.”

Some of the companies that Ziegler has invested in to date include:

K4Connect, which has created products for older adults and individuals living with disabilities that integrate the latest in smart home automation into a single responsive system.

VirtuSense, which has developed a system that identifies fall-risk through movement data analytics, machine vision, and artificial intelligence algorithms to transform functional movement into measurable data.

Breezie, an open platform that enables senior care providers to deliver care and services through a simple and personalized tablet interface.

Embodied Labs, which has developed a VR-enabled immersive learning system that gives professional and family caregivers insights that improve the way they view and provide care.

Caremerge, which has developed a cloud based software solution for independent and assisted living  facilities that includes care coordination, staff efficiency, family engagement and resident focused modules.

Third Eye Health, which pairs intuitive technology with accomplished physicians to provide telehealth-based medical care to post-acute and long term care patients.

Image credit: Ziegler Link-Age Fund

1 COMMENT

Comments are closed.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...

Longevity supplements report: Seneque profile

Seneque's supplement Elevant Prime seeks to promote vitality by recharging energy, repairing cells and rewinding age. Over the coming weeks, we will be bringing you...

Juvenescence debuts ketosis longevity supplement drink

Biotech Juvenescence's new product Metabolic Switch is a drink that supports healthy aging and a healthy metabolism by generating a state of ketosis. It's been...

AXA and Microsoft launch one-stop digital health platform

Microsoft joins forces with AXA for ‘one-stop’ digital healthcare platform. One of Europe's leading insurance companies AXA has announced it has formed a partnership with...

Targeting neurodegeneration with $82m Series A

Alchemab raises £60 million to advance novel platform for identifying disease-modifying antibody therapeutics for neurodegeneration, cancer and more. UK-based biotech Alchemab Therapeutics has secured a...
Supps report ad middle